Physician profile
David A Cohen
NPI 1649205790
$5,167.39
in general payments reported to CMS, 2019-2025
31 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $473 · 2021: $11.62 · 2022: $256 · 2023: $1,046 · 2024: $1,868 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.56 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $729.16 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $577.86 | 2019-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $466.68 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $247.87 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.17 | 2020-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $188.50 | 2024 | Omvoh |
| Celgene Corporation | $184.54 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $147.67 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $140.76 | 2019-2023 | Stelara |
| Pfizer INC. | $134.22 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $127.57 | 2019-2024 | Linzess |
| Allergan, INC. | $89.78 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $89.66 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $53.80 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $52.25 | 2019-2020 | |
| Medtronic, INC. | $44.51 | 2022-2023 | Pillcam |
| Ucb, INC. | $43.61 | 2019 | |
| Redhill Biopharma INC. | $41.88 | 2020 | |
| Ferring Pharmaceuticals INC. | $40.38 | 2019 | |
| Ardelyx, INC. | $37.36 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.12 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $28.11 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $28.04 | 2024 | Iqirvo |
| Aimmune Therapeutics, INC. | $26.88 | 2024 | |
| Concordia Pharmaceuticals INC. | $21.73 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.53 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $19.76 | 2023 | |
| Shield Therapeutics INC | $18.62 | 2024 | |
| Shire North American Group INC | $15.06 | 2019 | |
| Alfasigma USA, INC. | $14.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.